Lee Chan-jin, head of South Korea's Financial Supervisory Service (FSS), acknowledged that the review process for single-stock leveraged ETFs was expedited to meet the scheduled launch date. This accelerated review allowed 16 such ETF products to debut on May 27. The decision to speed up the process has drawn attention from lawmakers, indicating potential regulatory scrutiny or adjustments ahead. Investors should watch for any regulatory updates that could impact these leveraged ETFs going forward.
The recent developments around single-stock leveraged ETFs in South Korea provide context for crypto market watchers. For readers following major cryptocurrencies on Pluang, here is the market snapshot as of Oct 19, 2026 22:31 WIB: out of 50 major cryptocurrencies, 41 rose and 8 fell today. Notable movers include SNX at Rp3.868 (+3.17%), XRP at Rp23.517 (+3.09%), and LINK at Rp216.624 (+3.03%), with XRP showing a typical hold time of 72 days and a near-even Pluang order activity split of 49% Sell and 51% Buy.
Disc Medicine's stock surged 38% following positive Phase 3 trial results for its drug bitopertin, which showed efficacy and safety in treating erythropoietic protoporphyria. BMO Capital raised its price target from $100 to $120 and maintained an Out...
Qualcomm executive Ann C. Chaplin sold 1,827 shares of the company's stock for $319,268.25 under a Rule 10b5-1 trading plan, reducing her holdings by 6.62%. Qualcomm's stock price recently traded below its 50-day and 200-day moving averages, signalin...
BOK Financial is set to announce its Q3 2026 earnings after market close on October 19, with analysts forecasting earnings per share between $2.52 and $2.54 and revenue near $571 million. The company has a strong history of surpassing earnings estima...
AIBotics has completed the acquisition of NovaCore Labs' assets from PlayJamaica Limited, gaining technology, software, drones, mapping equipment, and customer contracts. This move expands AIBotics' platform in Jamaica and the Caribbean, enhancing AI...
EyePoint's stock dropped sharply after its DURAVYU treatment did not meet the primary endpoint in a Phase 3 trial for wet age-related macular degeneration (wet AMD). Although DURAVYU showed some vision improvement and reduced the need for additional ...
